Sunday, Sep 20, 2020 | Last Update : 03:34 AM IST

179th Day Of Lockdown

Maharashtra114584081235431351 Andhra Pradesh6095585198915244 Tamil Nadu5309084757178685 Karnataka5029823940257808 Uttar Pradesh3362942632884771 Delhi2347011981034877 West Bengal2155801870614183 Odisha167161133466722 Telangana1670461353571016 Bihar164224149722855 Assam150349121610528 Kerala12221687341490 Gujarat119088999083271 Rajasthan109088906851293 Haryana103773816901069 Madhya Pradesh97906743981877 Punjab90032658182646 Chhatisgarh7777541111628 Jharkhand6710052807590 Jammu and Kashmir5971138521951 Uttarakhand3713924810460 Goa2678320844327 Puducherry2142816253431 Tripura2069612956222 Himachal Pradesh11190691997 Chandigarh92566062106 Manipur8430653951 Arunachal Pradesh6851496713 Nagaland5306407910 Meghalaya4356234232 Sikkim2119178923 Mizoram15069490
  Business   Companies  13 Aug 2020  India's cheapest remdesivir version launched by Zydus Cadila at Rs 2,800 per vial

India's cheapest remdesivir version launched by Zydus Cadila at Rs 2,800 per vial

REUTERS
Published : Aug 13, 2020, 11:01 am IST
Updated : Aug 13, 2020, 11:01 am IST

The drug will be sold under the brand name Remdac to government and private hospitals treating COVID-19 patients

 Zydus Cadila launched the cheapest generic version of Gilead Sciences’ antiviral drug remdesivir in India. (Photo- Twitter)
  Zydus Cadila launched the cheapest generic version of Gilead Sciences’ antiviral drug remdesivir in India. (Photo- Twitter)

BENGALURU: Zydus Cadila on Thursday launched the cheapest generic version of Gilead Sciences’ antiviral drug remdesivir in India to treat COVID-19 following reports of shortages at hospitals in the world’s third-worst hit nation.

Zydus has priced it at 2,800 rupees ($37.44) per 100mg vial. It will be sold under the brand name Remdac to government and private hospitals treating COVID-19 patients, the company said in a regulatory filing.

 

Officials in some Indian states had a few weeks ago complained of supply issues, but a top executive at drugmaker Cipla Ltd had earlier this week said the supplies were stabilising.

Zydus is the fifth company to launch a copy of the antiviral in India after privately held Hetero Labs Ltd, Cipla, Mylan NV and Jubilant Life Sciences Ltd.

Gilead has also entered into licensing agreements with Dr. Reddy’s Laboratories Ltd and Syngene International Ltd to make remdesivir for distribution in 127 countries, including India.

India has reported a daily jump of more than 50,000 coronavirus infections for two weeks, with total cases as of Wednesday at 2.33 million.

 

Tags: zydus cadila, gilead sciences, antiviral drug, remdesivir, india, covid-19
Location: India, Karnataka, Bengaluru